Drug interactions
Eptifibatide + Selumetinib
Severity: Moderate
Eptifibatide and Selumetinib: moderate interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Selumetinib labeling notes increased bleeding risk with antiplatelet agents and vitamin K antagonists, and hemorrhage has occurred with the drug. Combined with eptifibatide, bleeding risk is likely to be increased.
What this interaction means in plain words
Eptifibatide and Selumetinib can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken.
Eptifibatide belongs to Cardiovascular; Selumetinib belongs to Oncology.
Why it happens
Additive bleeding risk; selumetinib hemorrhagic effects are not fully explained and add to glycoprotein IIb/IIIa platelet inhibition.
What to do
Monitor for bleeding signs and hemoglobin during co-use. Reassess the need for the combination if bleeding occurs.
What to ask your pharmacist
- Should I take them at different times of day?
- Does the dose of either medicine need to change?
- Is there anything I should avoid, such as alcohol or certain foods, while on both?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Eptifibatide and Selumetinib, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 7 days on the web. No card needed.
Other interactions of Eptifibatide
Other interactions of Selumetinib
Frequently asked questions
Can I take Eptifibatide with Selumetinib?
MediHelp rates the interaction as moderate. Eptifibatide and Selumetinib can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken. Selumetinib labeling notes increased bleeding risk with antiplatelet agents and vitamin K antagonists, and hemorrhage has occurred with the drug. Combined with eptifibatide, bleeding risk is likely to be increased.
How serious is the interaction between Eptifibatide and Selumetinib?
MediHelp rates it moderate, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Monitor for bleeding signs and hemoglobin during co-use. Reassess the need for the combination if bleeding occurs.
What other medicines interact with Eptifibatide?
MediHelp also lists interactions of Eptifibatide with, for example, Abrocitinib, Acalabrutinib, Acetylsalicylic acid. The full list is on the Eptifibatide page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
